In brief, PTPRD/PTPRT mutant patients had higher levels of immune cell infiltration, MHC I expression, and other immune signatures, indicating enhanced anti-tumor immunity in PTPRD/PTPRT mutant patients. This evidence concerns the gene PTPRD and neoplasm.